Peginterferon alfa-2a Injection Shortage
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Peginterferon alfa-2a Injection (PEGASYS) is currently in shortage, with one presentation unavailable from the sole manufacturer.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on June 12, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Peginterferon alfa-2a.
What's in Shortage
Peginterferon alfa-2a Injection (brand name: PEGASYS) is listed as a current shortage. The dosage form is Injection and it belongs to the therapeutic category Antiviral. The shortage was first posted on 01/24/2025 and last updated on 06/01/2026.
Which Manufacturers Are Affected
- pharmaand GmbH (pharma&): Available for Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4). Contact: 800-506-8501, email: medinfo.us@pharmaand.com
- pharmaand GmbH (pharma&): Unavailable for Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1). Product replenishment timeline to be confirmed sometime in Q1 2027 or earlier. Contact: 800-506-8501, email: medinfo.us@pharmaand.com
Why There's a Shortage
No specific reason for the shortage was provided in the source data.
What Patients Should Do
Patients who depend on this medication should talk to their pharmacist about current availability. They may also contact the manufacturer directly using the information above. Always consult your healthcare provider before making any changes to your treatment. This article does not provide medical advice.
Source
FDA Drug Shortage Database
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,153 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to June 12, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.